Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hege Kileng
Observed names:
H. Kileng,
Kileng, H.,
Kileng, Hege
Institutions:
University Hospital of North Norway,
UiT The Arctic University of Norway
Observed institutions:
University Hospital of North Norway,
UiT The Arctic University of Norway
ORCID:
0000-0002-5798-3242
Observed ORCID:
0000-0002-5798-3242
OpenAlex ID:
A5023167132
Hepatitis C reinfection after sustained virological response
2016
·
Håvard Midgard
, Benedikte Bjøro
, et al.
·
Journal of Hepatology
·
141
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
2022
·
Anita Y.M. Howe
, Chaturaka Rodrigo
, et al.
·
JHEP Reports
·
59
PDF
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
2016
·
Jan Sperl
, Gabor Horvath
, et al.
·
Journal of Hepatology
·
55
Long-Term Results after Anterior Sphincteroplasty for Anal Incontinence
2009
·
K. Mevik
, S. Norderval
, et al.
·
Scandinavian Journal of Surgery
·
37
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
2022
·
Rasmus Goll
, Øystein K. Moe
, et al.
·
BMC Gastroenterology
·
25
PDF
Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study
2019
·
H. Kileng
, T. Gutteberg
, et al.
·
BMC Infectious Diseases
·
19
PDF
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
2019
·
Midori Kjellin
, Hege Kileng
, et al.
·
Scandinavian Journal of Gastroenterology
·
17
PDF
Repeated intensified infliximab induction – results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm
2016
·
Kay-Martin Johnsen
, Rasmus Goll
, et al.
·
European Journal of Gastroenterology & Hepatology
·
15
Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway
2017
·
H. Kileng
, L. Bernfort
, et al.
·
BMC Infectious Diseases
·
13
PDF
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
2022
·
Kay-Martin Johnsen
, Jon Florholmen
, et al.
·
BMC Gastroenterology
·
8
PDF
Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014–2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy
2018
·
Hege Kileng
, Midori Kjellin
, et al.
·
Scandinavian Journal of Gastroenterology
·
4
PDF
Chronic hepatitis C: Epidemiology, viral resistance, and public health implications
2019
·
Hege Kileng
·
NORA - Norwegian Open Research Archives
·
1
C-Edge Head-to-Head: Efficacy and Safety of Elbasvir and Grazoprevir Compared with Sofosbuvir/Pegylated Interferon/Ribavirin: A Phase 3 Randomized Controlled Trial
2016
·
J. Sperl
, G. Horvath
, et al.
·
Journal of Hepatology
·
1
Nobelpris for oppdagelsen av hepatitt C-viruset
2020
·
Hege Kileng
·
Tidsskrift for Den norske legeforening
PDF
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
2019
·
Kjellin, Midori
, Kileng, Hege
, et al.
·
Figshare
Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype la and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs) : Real-life experience from a multicenter study in Sweden and Norway
2016
·
Hege Kileng
, Midori Kjellin
, et al.
·
Hepatology
Show more works
View as search
Works count:
26
Citation count:
395
H-index:
9
I10-index:
9
Year
Topic
Type